Biotech stocks may offer your portfolio an element of growth, and that's because these companies are sharply focused on ...

ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory ...

Shares in the Danish biotech fell 32 per cent in Copenhagen after phase 2 clinical trial data for its drug petrelintide showed patients lost 10.7 per cent of their body weight on average after 42 ...

March 6 (Reuters) - Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

It's also worth noting that Amarin is engaged in a legal battle with generic-drug maker Hikma Pharmaceuticals, claiming that ...

From billion-dollar licensing deals to advances in cancer therapies and artificial intelligence, Chinese biotech firms are ...

TrialAssure announced today announced the launch of its AI in Medical Writing Certification (AIMWC) Program, a new ...